YOU KNOW YOUR PATIENTS—DO YOU KNOW IF THEY’RE ELIGIBLE FOR CARVYKTI®?

Key Eligibility Criteria1,2

  • Adults with RRMM
  • ≥1 prior LoT, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID)
  • Refractory to lenalidomide
  • High- or standard-risk cytogenetics*
  • Naive, exposed, or refractory to anti-CD38 monoclonal antibodies
  • ECOG PS 0 or 1

Additional Considerations1,2

  • No prior CAR-T or BCMA targeting therapies
  • No known active or prior history of central nervous system involvement
  • Does not exhibit clinical signs of meningeal involvement of multiple myeloma
  • No history of Parkinson's disease or other neurodegenerative disorder

BCMA=B-cell maturation antigen; CAR-T=chimeric antigen receptor-T cell; CD38=cluster of differentiation 38; del=deletion; ECOG PS=Eastern Cooperative Oncology Group performance score; gain/amp=gain or amplification; LoT=line(s) of therapy; RRMM=relapsed or refractory multiple myeloma; t=translocation.

*High-risk cytogenetics defined as gain/amp (1q), del(17p), t(4;14), t(14;16), with ≥2 high-risk abnormalities, or with del(17p), t(4;14), or t(14;16).

Consider CARVYKTI® for patients as early as first relapse1,2†

2L CARVYKTI® Patients

These are examples of patients who were evaluated and prescribed CARVYKTI® as their second LoT.

Terry, headshot (patient portrayal)

Patient portrayal.

Terry

Clinical Considerations

  • 55 years old
  • High-risk cytogenetics
  • ECOG PS: 0
  • Transplant-eligible

Treatment History

  • 1L: DVRd→SCT→R maintenance
    • Progression after 36 months
Margaret, headshot (patient portrayal)

Patient portrayal.

Margaret

Clinical Considerations

  • 70 years old
  • Standard-risk cytogenetics
  • ECOG PS: 0
  • Transplant-eligible

Treatment History

  • 1L: VRd→SCT→R maintenance
    • Progression after 60 months

See The Data Behind Patient Outcomes

VIEW CARTITUDE-4 EFFICACY

3L CARVYKTI® Patients

These are examples of patients who were evaluated and prescribed CARVYKTI® as their third LoT.

Chris, headshot (patient portrayal)

Patient portrayal.

Chris

Clinical Considerations

  • 67 years old
  • Standard-risk cytogenetics
  • ECOG PS: 0
  • Transplant-eligible/deferred

Treatment History

  • 1L: VRd→SCT→R maintenance
    • Progression after 40 months
  • 2L: DKd
    • Progression after 20 months
Lucy, headshot (patient portrayal)

Patient portrayal.

Lucy

Clinical Considerations

  • 78 years old
  • Standard-risk cytogenetics
  • ECOG PS: 1
  • Transplant-ineligible

Treatment History

  • 1L: DRd
    • Progression after 42 months
  • 2L: PVd
    • Progression after 12 months

See The Data Behind Patient Outcomes

VIEW CARTITUDE-4 EFFICACY

1L=first-line; 2L=second-line; 3L=third-line; DKd=daratumumab, carfilzomib, dexamethasone; DRd=daratumumab, lenalidomide, dexamethasone;

DVRd=daratumumab, bortezomib, lenalidomide, dexamethasone; ECOG PS=Eastern Cooperative Oncology Group performance status;

PVd=pomalidomide, bortezomib, dexamethasone; R=lenalidomide; SCT=stem cell transplant; VRd=bortezomib, lenalidomide, dexamethasone.

†Patient cases do not represent all characteristics for CARVYKTI® eligibility.

GET IN
TOUCH

Find A CARVYKTI® Activated Treatment Center Near You

FIND AN Activated TREATMENT CENTER